Mobilization by Plerixafor of Haematopoietic Stem Cells in Children

• Status: Completed
• Trial end date: 2011-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a prospective Phase II, monocentre study.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Clermont-Ferrand
• Treatments: JM 3100; Plerixafor

Criteria

Inclusion Criteria:

• 0 to 18 years old

• Solid malign tumor

• Lansky score ≥ 70%

• Indication of hematopoietic stem cell taking by cytapheresis for extensive chemotherapy followed by one or several reinjections of hematopoietic stem cells

Exclusion Criteria:

• Administration of hematopoietic growth factors in 8 days preceding the injection of Plerixafor.

• Contraindication in the cytapheresis or in the extensive chemotherapy.

• Clinical or biological state dissuading the realization of the cytapheresis

• Chemotherapy in 15 days preceding the injection of plerixafor or neutrophils < 1500/mm3